A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

NCT06142617 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Immune Checkpoint Inhibitor
EGFR Exon 21 Mutation

Interventions

DRUG: Pembrolizumab, pemetrexed, platinum
DRUG: Osimertinib

Sponsor

Peking Union Medical College Hospital